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SCIENTIFIC EDITORIAL
Should  we  administrate  anticoagulants  to
critically  ill  patients  with  new  onset
supraventricular  arrhythmias?
Faut-il  anticoaguler  les  patients  hospitalisés  en  réanimation  ayant  un  trouble
du rythme  supraventriculaire  de  novo  ?
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atrial  tachysystolia)  is  the  most  frequent  rhythm  disorder  in  surgical  and  non-surgical  inten-
sive  care  units  (ICUs),  occurring  in  4.5%  to  46%  of  critically  ill  patients  [1—5]. Although  SVA
in  critically  ill  patients  is  now  recognized  as  an  indicator  of  illness  severity,  its  independent
relationship  with  mortality  is  the  subject  of  debate  [1,4—6].  Regarding  morbidity,  recentAnticoagulation;
Intensive  care  unit;
Thromboembolism
data  show  that  in-hospital  arterial  thromboembolic  events  (ATEs)  are  not  rare  [5]. A  mul-
ticentre  retrospective  study,  with  approximately  50,000  patients  hospitalized  for  severe
sepsis,  reported  that  SVA  was  associated  with  an  increased  adjusted  risk  of  in-hospital
ischaemic  stroke  (2.6%  vs  0.6%;  odds  ratio  2.70  [2.05—3.57];  P  <  0.001)  [5].
Abbreviations: ATE, Arterial thromboembolic event; CHADS2, Cardiac failure, hypertension, age, diabetes, stroke (doubled); CHA2DS2-
VASc, Congestive heart failure, hypertension, age ≥ 75 years (doubled), diabetes, stroke (doubled), vascular disease, age 65—74 years, Sex
category (female); LAA, Left atrial appendage; ICU, Intensive care unit; TOE, Transoesophageal echocardiography; SVA, Supraventricular
arrhythmia (atrial ﬁbrillation, atrial ﬂutter, atrial tachysystolia).
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In  cardiology  patients,  although  numerous  clinical  trials  have  provided  an  extensive  evi-
dence  base  for  the  use  of  antithrombotic  therapy  to  prevent  SVA-related  ATEs,  bleeding
risk  limits  its  administration  [7]. Antithrombotic  therapy  to  prevent  ATEs  is  recommended
by  the  European  Society  of  Cardiology  experts,  in  patients  at  intermediate  risk  or  high
risk  according  to  the  CHADS2 (Cardiac  failure,  hypertension,  age,  diabetes,  stroke  [dou-
bled])  and,  more  recently,  the  CHA2DS2-VASc  (Congestive  heart  failure,  hypertension,
age  ≥  75  years  (doubled),  diabetes,  stroke  [doubled],  vascular  disease,  age  65—74  years,
sex  category  [female])  risk  stratiﬁcation  scores  [7].  The  CHADS2 risk  score  is  based  on  a
points  system,  in  which  2  points  are  assigned  for  a  history  of  stroke  or  transient  ischaemic
ttack  and  1  point  is  assigned  for  each  of  the  following
tems:  age  >  75  years,  history  of  hypertension,  diabetes  or
ecent  cardiac  failure.  In  2001,  Gage  et  al.,  using  data  from
he  National  Registry  of  Atrial  Fibrillation,  validated  the
HADS2 score  for  predicting  1—3-year  stroke  rate  in  car-
iology  patients  aged  65—95  years  with  non-valvular  atrial
brillation  and  no  antithrombotic  therapy  at  discharge  [8].
o  improve  risk  stratiﬁcation,  Lip  et  al.  extended  the
HADS2 schema  in  2010,  by  considering  additional  stroke
isk  factors  (vascular  disease,  female  sex  and  age  ≥  75  years)
n  the  CHA2DS2-VASc  risk  score,  validated  to  predict  1-
ear  stroke  rate  in  cardiology  patients  with  non-valvular
trial  ﬁbrillation  and  no  vitamin  K  antagonist  or  heparin
reatment  at  discharge  [9].  To  balance  the  risk  of  stroke
gainst  the  risk  of  major  bleeding,  which  is  the  most
eared  complication  of  anticoagulation  therapy,  a  formal
leeding  risk  assessment  with  the  HAS-BLED  (hypertension,
bnormal  renal/liver  function,  stroke,  bleeding  history  or
redisposition,  labile  international  normalized  ratio,  elderly
age  >  65  years],  drugs/alcohol  concomitantly)  score  is  rec-
mmended  for  all  patients  with  atrial  ﬁbrillation  [7].
Recently,  the  American  Association  for  Thoracic  Surgery
eveloped  guidelines  for  the  prevention  and  treatment  of
erioperative/postoperative  atrial  ﬁbrillation  for  thoracic
urgical  procedures  [6].  Anticoagulation  within  the  ﬁrst  48  h
f  new  onset  atrial  ﬁbrillation  should  be  considered  based
n  the  patient’s  CHA2DS2-VASc  risk  score  (S)  for  stroke,
eighed  against  the  risk  of  postoperative  bleeding  (S  =  0:  no
nticoagulation  recommended;  S  =  1:  anticoagulation  should
e  considered  if  its  beneﬁts  outweigh  the  risk  of  bleed-
ng;  S  =  2:  anticoagulation  is  highly  recommended  if  its
eneﬁts  outweigh  the  risk  of  bleeding;  class  I  recommenda-
ion).  However,  this  suggested  perioperative/postoperative
hromboembolic  risk  stratiﬁcation  is  based  on  indirect  evi-
ence  from  studies  outside  of  the  perioperative  setting,
nvolving  patients  with  chronic  non-valvular  atrial  ﬁbrilla-
ion  and  no  antithrombotic  therapy  [7].  Moreover,  no  scoring
ystem  is  recommended  by  these  guidelines  for  identify-
ng  the  risk  of  bleeding  after  initiation  of  anticoagulation
7].
In  surgical  and  non-surgical  critically  ill  patients  with
VA,  excluding  patients  in  the  postoperative  stage  of  cardiac
urgery,  a  single-centre  prospective  study  by  Champion  et  al.
valuated  the  CHADS2 and  CHA2DS-VASc  risk  scores  in  the
rediction  of  SVA-related  ATEs  for  the  ﬁrst  time  [10].  Cham-
ion  et  al.  reported  16  in-hospital  SVA-related  ATEs  in  12  of
08  (11%)  patients,  including  ﬁve  strokes,  three  mesenteric
stenosis  and  the  patient’s  history  of  stroke  were  signiﬁcantly
related  to  the  onset  of  ATEs.  The  most  accurate  threshold
for  predicting  an  ATE  was  a CHADS2 score  of  ≥  4.  Previous
stroke  was  the  only  predictive  factor  for  ATEs  in  SVA  patients
[10]. We  cannot,  however,  conclude  that  the  CHADS2 risk
score  can  predict  SVA-related  ATEs  in  critically  ill  patients
on  the  basis  of  this  single-centre  study.  First,  risk  scores
were  validated  in  a  homogeneous  cardiology  population  with
non-valvular  atrial  ﬁbrillation  and  no  antithrombotic  ther-
apy.  Champion  et  al.  attempted  to  validate  these  scores  in
a  different  heterogeneous  population  that  included  valvular
SVA  and  patients  with  antithrombotic  therapy  [10].  Second,
the  authors  report  a higher  incidence  of  SVA-related  ATEs
(11%)  than  the  incidence  described  previously  in  ICUs  [5].
The  inclusion  of  patients  with  valvular  SVA  (mitral  stenosis)
and  those  with  a  history  of  SVA  may  explain  these  results
in  part.  Third,  the  main  outcome  variable  was  onset  of  an
ATE,  including  clinical  and  echocardiographic  (LAA  throm-
bus  detected  by  echocardiography)  events,  even  though
LAA  thrombus  itself  is  a major  risk  factor  for  clinical  ATEs.
Fourth,  the  decision  to  give  anticoagulants  cannot  be  based
on  a  CHADS2 score  ≥  4,  given  its  low  sensitivity  (50%)  and
low  positive  predictive  value  (26%)  in  predicting  SVA-related
ATEs  in  ICU  patients,  notably  because  of  their  increased
bleeding  risk  [10].
Given  that  neither  risk  factor  nor  risk  stratiﬁcation  strat-
egy  is  validated  in  the  ICU  setting,  the  assessment  of  the
SVA-related  ATE  risk  in  critically  ill  SVA  patients,  particu-
larly  in  the  perioperative  phase  of  thoracic  surgery,  is  based
on  studies  in  a  cardiology  population  [6].  Recommendations
for  the  prevention  of  ATEs  with  long-term  antithrombotic
therapy  in  cardiology  patients  are  based  on  the  presence
(or  absence)  of  clinical  and  echocardiographic  risk  factors
for  ATE  with  CHADS2 and  CHA2DS2-VASc  risk  stratiﬁcation
scores.  In  particular,  recent  European  Society  of  Cardi-
ology  guidelines  recommend  an  anticoagulation  strategy
before  elective  cardioversion  (spontaneous,  electrical  or
pharmacological)  of  SVA  in  patients  with  stable  haemody-
namics:  the  strategy  depends  on  whether  the  duration  of
the  SVA  is  <  48  h  or  >  48  h  [7].  Since  the  1990s,  several  obser-
vational  transoesophageal  echocardiography  (TOE)  studies
have  demonstrated  LAA  thrombus  in  0%  to  27%  of  patients
with  SVA  of  >  48  h  duration  [11—13].  Although  LAA  thrombi
have  been  identiﬁed  by  TOE  within  shorter  intervals  [13],
recommendations  are  based  on  the  assumption  that  a  LAA
thrombus  requires  a  minimum  of  48  h  to  form  after  the  onset
of  SVA.  Because  of  the  strong  correlation  with  pericardiover-nfarctions,  two  limb  ischaemias,  two  embolic  myocardial
nfarctions  and  four  left  atrial  appendage  (LAA)  thromboses.
he  CHADS2 and  CHA2DS2-VASc  scores,  previous  SVA,  mitral
s
w
fion  ATEs,  a  thrombus  in  the  left  atrium  or  LAA  detection
ith  TOE  prohibit  cardioversion  and  require  anticoagulation
or  at  least  3  weeks  [7].
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These  results  from  cardiology  patients  still  remain  to
be  demonstrated  in  surgical  and  non-surgical  critically
ill  patients.  In  fact,  the  frequency  of  and  the  required
time  for  LAA  thrombus  formation  in  critically  ill  patients
with  SVA  are  possibly  different  in  the  case  of  cardiol-
ogy  patients.  Champion  et  al.  reported  a  high  incidence
of  ATEs  and  described  an  LAA  thrombus  in  four  of  108
patients  (3.7%),  although  the  duration  of  SVA  was  systemati-
cally  <  48  h  [10].  Moreover,  the  incidence  of  LAA  thrombus  is
possibly  underestimated,  as  TOE  was  not  systematically  per-
formed;  transthoracic  echocardiography  without  TOE  leads
to  LAA  thrombus  detection  with  very  low  sensitivity.  There-
fore,  these  data  could  suggest  a  incidence  of  in-hospital
ATEs  (11%)  that  is  higher  than  that  observed  in  cardiology
patients  (2.3%  stroke  rate  at  1  year  [9]),  despite  the  SVA
duration  being  usually  <  48  h  [1,2,10].  Intracardiac  throm-
bus  formation  in  cardiology  patients  with  SVA  begins  with
Virchow’s  triad  of  stasis,  endothelial  dysfunction  and  a
hypercoagulable  state.  Exacerbation  of  these  pathophysio-
logical  mechanisms  in  critically  ill  patients  presenting  severe
inﬂammation  or  sepsis  [14,15]  could  explain  the  results
reported  by  Champion’s  group.  So,  preventing  the  SVA-
related  ATE  risk  that  occurs  in  ICUs  requires  speciﬁc  studies
for  this  very  speciﬁc  population.
As  we  are  unaware  of  any  studies  reporting  the  frequency
and  required  time  for  LAA  thrombus  formation  in  critically
ill  patients  with  SVA,  the  anticoagulation  strategy  in  this
context  is  not  consensual.  Thus,  some  studies  reported  that
therapeutic  anticoagulation  is  prescribed  for  16%  to  58%  of
critically  ill  patients  with  SVA  [1,10].  As  these  patients  who
received  systemic  anticoagulation  had  a  high  frequency  of
major  bleeding  events  (9%  to  45%  depending  on  the  study
[2,10]),  we  recommend  administering  anticoagulation  only
in  patients  with  the  highest  ATE  risk.
To  identify  SVA-related  ATE  risk  factors  in  critically
ill  patients,  we  have  begun  a  TOE  multicentre  prospec-
tive  observational  study  (No ID-RCB:  2014-A00463-44).  The
objective  of  this  study  is  to  determine  the  clinical  and
echocardiographic  risk  factors  for  ATEs  and,  particularly,
to  determine  the  frequency  and  the  required  time  for  LAA
thrombus  formation  in  patients  with  new  onset  SVA  in  ICUs.
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